National Institutes of Health

Morehouse School of Medicine, located in Atlanta, Georgia, is a historically Black college and university (HBCU) dedicated to training healthcare professionals, with a special emphasis on minority students. The institution offers a medical degree program along with master’s degrees in various fields, including Public Health and Biomedical Sciences. Medical students can specialize in areas such as Family Medicine, Internal Medicine, Obstetrics and Gynecology, Pediatrics, Psychiatry, and Surgery, completing clinical assignments at affiliated hospitals. The school is also engaged in research, focusing on cardiovascular studies, neuroscience, and health disparities. To support its mission, Morehouse manages an endowment fund, the earnings of which are utilized for scholarships, research funding, and academic programs. Admissions requirements vary by program, and the school provides scholarships aimed at supporting disadvantaged students, alongside academic and merit-based financial aid.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

The Georgia Clinical & Translational Science Alliance (Georgia CTSA) is an inter-institutional magnet that concentrates basic, translational, and clinical research investigators, community clinicians, professional societies, and industry collaborators in dynamic clinical and translational research projects. Emory engaged three of its close academic partners - Morehouse School of Medicine (MSM), Georgia Institute of Technology (Georgia Tech), and the University of Georgia (UGA) - to form the Georgia CTSA. This partnership, a strategic multi-institutional alliance, offers compelling, unique, and synergistic advantages to research and patients statewide. Emory is a national leader in healthcare and biomedical research as well as an outstanding leader in clinical and translational research training and education. Morehouse School of Medicine is a nationally recognized historically black institution that brings ethnic diversity to biomedical research, addresses health disparities through successful community engagement research, and serves as a pipeline for training minority researchers. Georgia Tech is a national leader in biomedical engineering and the application of innovative systems engineering to healthcare solutions. UGA has a proven track record in outstanding basic and translational research and, as the State’s land-grant institution, offers a robust statewide network that enhances community outreach, service, and research. These institutions extend their current partnerships in healthcare, education, and cutting-edge interdisciplinary research to synergize Georgia CTSA. Created in 2017 as one of a national consortium striving to improve the way biomedical research is conducted across the country. The consortium, funded through the National Center for Advancing Translational Sciences, part of the National Institutes of Health's Clinical and Translational Science Awards (CTSA), shares a common vision to translate laboratory discoveries into treatments for patients, engage communities in clinical research efforts and train the next generation of clinical investigators.

Augusta University, founded in 1785 and located in Augusta, Georgia, is the oldest postsecondary institution in the state. It offers a diverse range of academic programs across nine colleges, including the Medical College of Georgia, the Hull College of Business, and the Dental College of Georgia. The university serves nearly 9,000 students and provides associate’s, bachelor’s, and master’s degrees, as well as several pre-professional programs in healthcare fields such as medicine, dental, veterinary, and pharmacy. Augusta University is distinguished by its status as the only public academic medical center in Georgia, where world-class clinicians deliver innovative patient care. Additionally, the institution offers continuing education programs aimed at professional development and personal enrichment. Financial aid options, including scholarships and state aid, are available to support eligible students in their educational pursuits.

Metaclipse Therapeutics is an early-stage biotechnology company focused on developing personalized cancer immunotherapies. Founded in 2010 and based in Atlanta, Georgia, the company is engaged in the creation of Membrex, a novel treatment that utilizes modified tumor-membrane vesicles derived from a patient's own tumor tissue. These vesicles are augmented with clinically proven immunostimulatory proteins using a proprietary method. The resulting product is designed to activate the body's immune system, enabling it to target and attack metastatic cancer cells effectively. Metaclipse's therapies are aimed at treating various cancer types, including breast, prostate, renal, melanoma, and lymphoma. The company plans to commercialize its products through licensing agreements with major pharmaceutical firms after establishing their safety and efficacy.

Emory University is a public research university located in Atlanta, Georgia. It offers a range of undergraduate and graduate programs across various fields. The institution generates over $500 million in research funding annually while prioritizing teaching. Emory collaborates with local schools and partners to enhance its educational impact. The university's campus is in the historic Druid Hills area, and its connection to Atlanta shapes it. President James W. Wagner acknowledges the contributions of faculty, staff, students, and alumni to the university's mission and its commitment to improving what is considered good​.

Emory University is a public research university located in Atlanta, Georgia. It offers a range of undergraduate and graduate programs across various fields. The institution generates over $500 million in research funding annually while prioritizing teaching. Emory collaborates with local schools and partners to enhance its educational impact. The university's campus is in the historic Druid Hills area, and its connection to Atlanta shapes it. President James W. Wagner acknowledges the contributions of faculty, staff, students, and alumni to the university's mission and its commitment to improving what is considered good​.

Galectin Therapeutics is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources. Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy. Galectin Therapeutic stock is traded on the NASDAQ under the symbol GALT. The company is located in a suburb of Atlanta known as Norcross, Georgia USA